Ref-1在肿瘤放射治疗策略中的实验研究的开题报告.docx

APE1/Ref-1在肿瘤放射治疗策略中的实验研究的开题报告 Title：The Experimental Research of APE1/Ref-1 in Tumor Radiotherapy Strategies Introduction： APE1/Ref-1 (apurinic/apyrimidinic endonuclease/ redox factor-1) is a multifunctional protein that plays a critical role in DNA damage repair, redox signaling, and transcriptional regulation. APE1/Ref-1 has been found to be overexpressed in many types of tumors, and its expression is associated with tumor progression, recurrence, and resistance to chemotherapy and radiotherapy. Therefore, it is an attractive target for the development of new anticancer therapies. Radiotherapy is a widely used treatment for cancer, which uses ionizing radiation to kill cancer cells. However, the response of cancer cells to radiation therapy is highly variable, and many tumors develop resistance to this treatment. Therefore, there is an urgent need to identify novel targets to improve the efficacy of radiotherapy for cancer. Hypothesis: APE1/Ref-1 may play a critical role in tumor radiotherapy response by regulating DNA damage repair, redox signaling, and transcriptional regulation. Targeting APE1/Ref-1 may enhance the efficacy of radiotherapy for cancer. Objectives: The objectives of this study are to investigate the role of APE1/Ref-1 in tumor radiotherapy response and to evaluate the potential of targeting APE1/Ref-1 as a novel strategy to improve the efficacy of radiotherapy for cancer. Methods: 1. Cell culture and radiation treatment: The expression of APE1/Ref-1 in different cancer cell lines will be determined by Western blotting. The cells will be irradiated at different doses (2, 4, 6 Gy) using an X-ray source, and cell survival will be measured by the clonogenic assay to evaluate the radiosensitivity of the cells. 2. APE1/Ref-1 knockdown and overexpression: The APE1/Ref-1 expression in the cells will be modulated using siRNA or plasmid transfection. The effects of APE1/Ref-1 knockdown or overexpression on the radiosensitivity of the cells will be evaluat